ArticleScientific reports2026
High efficiency of antibacterial activity-based Zn-Co@BTC MOF against Bacillus bacterial cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Zn(II) Coordination Polymer Assembled from Pyridazine-Tetracarboxylate: Single-Crystal X-ray Structure, Hirshfeld Surface Analysis, and Bifunctional Fluorescence Sensing Toward Cu²⁺ and Tetracycline.Journal of fluorescence · 2026Article
- Design, synthesis, and anticancer evaluation of a novel imine-linked covalent organic framework correlated to molecular docking and DFT insights.RSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, Zn-Co@BTC was synthesized under environmentally friendly, economical, and green conditions. It was prepared by the solvothermal method using zinc nitrate hexahydrate and cobalt nitrate hexahydrate as the metals, with benzene-1,3,5-tricarboxylate (BTC) as the ligand. The formation of Zn-Co@BTC MOF was confirmed by Ultraviolet-Visible spectroscopy (UV-Vis), X-ray diffraction, Fourier transform infrared, thermogravimetric analysis, Raman spectroscopy, X-ray Photoelectron Spectroscopy, Brunauer-Emmett-Teller surface area analysis, scanning electron microscopy, and Transmission electron microscopy. It exhibited high thermal stability, a large surface area, and strong antibacterial activity. The antibacterial activity was evaluated against the Bacillus cereus strain identified by 16S rRNA gene sequencing using optical density measurements and the cut plug method. The results showed remarkable antibacterial activity, achieving near-complete bacterial growth inhibition (99.9%) at 600 mg/L and complete inhibition (100%) at a concentration of 800 mg/L. These findings support the potential use of Zn-Co@BTC MOF as an antibacterial agent in biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.